Merck Tops Q3 Estimates and Raises Profit Outlook Amid Keytruda Sales Surge
Merck reported Q3 revenue of $18.09B, up 5% YoY, beating estimates. Adjusted EPS was $2.49, exceeding expectations. Keytruda sales hit $8.60B, with new injectable version contributing $830M. Merck raised its adjusted profit forecast to $2.77-$2.82 per share and narrowed 2026 revenue guidance to $66.8B-$67.3B. The company is preparing for Keytruda patent expirations in 2028.
How this was made
The 30-second read
Why it matters
The article provides a first-hand earnings and guidance update with specific ranges, plus product-level sales beats (Keytruda, Winrevair, Gardasil) and a one-time licensing-related charge, all of which can drive repricing and positioning for the next earnings cycle.
Market read
Guidance raise plus product-level beats create a near-term catalyst for MRK positioning, while patent-expiry/generic competition remains the central medium-term risk.
What to watch
Winrevair and Gardasil strength are supportive, but animal health sales missed expectations, which could limit upside breadth across Merck’s portfolio.
Background
Merck’s Keytruda faces generic competition risk as key patents are set to expire in 2028; the company is promoting a newer injectable format (Keytruda Qlex) to defend share.
Ticker impact
Merck reported Q3 results that beat expectations and raised 2026 adjusted EPS and revenue guidance on Keytruda sales strength.
Likely upward bias as the market reprices Merck’s 2026 earnings power, tempered by concerns about patent expiry and the need to defend share via the new formulation.
The article discloses fresh, company-specific guidance ranges (adjusted EPS and revenue) and Q3 Keytruda sales beats, which are direct inputs to valuation and positioning.
Market effects
Reinforces bullish read-through for large-cap oncology immunotherapy demand and formulation transition strategies ahead of biosimilar/generic pressure.
Supports US large-cap pharma sentiment, potentially lifting peers with similar oncology franchises facing patent expiry.
Highlights ongoing global competition dynamics around Keytruda exclusivity and localized licensing-related charges.
Counterpoint
The guidance raise may be partly offset by the disclosed one-time licensing charge and the looming 2028 patent expiry, so the market may still discount durability of Keytruda share.
Key entities
- companyMerck
Reported Q3 results, raised adjusted EPS and narrowed 2026 revenue guidance, citing Keytruda sales and Keytruda Qlex contribution.
- productKeytruda
Immunotherapy drug whose Q3 sales and injectable Qlex contribution exceeded expectations in the article.
- companySciBrunch
Chinese cancer drugmaker referenced as the counterparty in a licensing agreement tied to a one-time charge.
- productWinrevair
Rare lung condition treatment with Q3 sales growth and an above-estimate print in the article.
- productGardasil
HPV vaccine with US sales above expectations in the article.
